{"id":"W4361812693","doi":"10.1158/1078-0432.c.6532290","title":"Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; National Institutes of Health; Breast Cancer Alliance; Sierra Oncology; Ipsen; Genentech; Deutsche Krebshilfe; G1 Therapeutics; Stand Up To Cancer; EMD Serono; Mersana Therapeutics; Merck KGaA; Dana-Farber/Harvard Cancer Center; GlaxoSmithKline; Breast Cancer Research Foundation; Pfizer; Symphogen; Carrick Therapeutics; American Association for Cancer Research; AstraZeneca; Eli Lilly and Company; Astex Pharmaceuticals","keywords":"Medicine; Olaparib; Internal medicine; Triple-negative breast cancer; Breast cancer; Oncology; Cohort; Cancer; BRCA mutation; PARP inhibitor; Adverse effect","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002463418,0.0008183136,0.001845336,0.0003188009,0.0004486694,0.001068233,0.0005093152,0.0008016526,0.009825318],"category_scores_gemma":[0.002777917,0.0003399249,0.001311685,0.0006549615,0.0003136329,0.0009458767,0.0003252382,0.002334218,0.001787002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006407153,"about_ca_system_score_gemma":0.001381413,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000622893,"about_ca_topic_score_gemma":0.001991573,"domain_scores_codex":[0.9990457,0.0005082056,0.00009156118,0.0001100523,0.0001675831,0.00007687456],"domain_scores_gemma":[0.99804,0.000559993,0.0004981037,0.0002204707,0.0002535079,0.0004279079],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.7089019,0.008124372,0.01454222,0.003714208,0.005064252,0.0003986483,0.0001963076,0.004455673,0.02032789,0.0005700504,0.06375423,0.1699501],"study_design_scores_gemma":[0.7016785,0.1484117,0.06751939,0.0005582402,0.003620822,0.001291151,0.0001215568,0.002330271,0.006403699,0.001474657,0.06647363,0.0001163526],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"dataset","genre_scores_codex":[0.836326,0.02055997,0.003330595,0.005662184,0.0008857221,0.009493915,0.0880909,0.0005488675,0.03510183],"genre_scores_gemma":[0.8963431,0.006628411,0.003045442,0.005435807,0.0004200518,0.007892024,0.07120045,0.0001453462,0.00888935],"genre_candidate":"dataset","genre_consensus":null,"teacher_disagreement_score":0.009825318,"threshold_uncertainty_score":0.03286898,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2190959038879521,"score_gpt":0.4841796982256646,"score_spread":0.2650837943377126,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}